Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. HIV infection is associated with type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. De novo electrocardiographic abnormalities in persons living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HIV infection is associated with thoracic and abdominal aortic aneurysms: a prospective matched cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Edwin DeJesus
  • Jürgen K Rockstroh
  • Keith Henry
  • Jean-Michel Molina
  • Joseph Gathe
  • Srinivasan Ramanathan
  • Xuelian Wei
  • Kitty Yale
  • Javier Szwarcberg
  • Kirsten White
  • Andrew K Cheng
  • Brian P Kearney
  • GS-236-0103 Study Team
  • Jan Gerstoft
Vis graf over relationer
The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.
OriginalsprogEngelsk
TidsskriftLancet
Vol/bind379
Udgave nummer9835
Sider (fra-til)2429-38
Antal sider10
ISSN0140-6736
DOI
StatusUdgivet - 2012

ID: 36458989